Chantix Increases The Chances Of Smoking Cessation
January 31, 2007
A review by Cochrane Collaborative states that the anti-smoking drug Chantix increases smoker's quit smoking success by several times.
The review report by Cochrane Collaborative was based on the outcome of the six Pfizer-sponsored clinical trials in which the anti-smoking performance of Chantix, anti-depressants and placebos were compared. Results showed that anti-depressants outperformed the effects of placebos by 2-1 while the Pfizer Incl. manufactured anti-smoking drug Chantix managed to score a 3-1 victory over the antidepressants.
Cochrane Collaborative`s study report has been published on the cyberspace as the Cochrane Library and is also easily available through subscription.